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Abstract
BACKGROUND: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL).
Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We
evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS:
We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to
receive FL alone or with oxatiplatin for six months. The primary end point was disease-free survival.
RESULTS: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9
months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with
293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The
rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in
the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL
group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile
neutropenia was 1.8 percent, the incidence of gastro-intestinal adverse effects was low, and the incidence of
grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-
up. Six patients in each group died during treatment (death rate, 0.5 percent). CONCLUSIONS: Adding
oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Keywords
cancer, fluorouracil, colon, oxaliplatin, treatment, adjuvant, leucovorin
Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences
Publication Details
Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M.,
Clingan, P., Bridgewater, J., Tabah-Fisch, I. & de Gramont, A. (2004). Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. New England Journal of Medicine, 350 (23), 2343-2351.
Authors
Thierry Andre, Corrado Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Tabernero, Tamas Hickish,
Clare Topham, Marta Zaninelli, Phillip Clingan, John Bridgewater, Isabelle Tabah-Fisch, and Aimery de
Gramont
This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/974
 




















Oxaliplatin, Fluorouracil, and Leucovorin 
as Adjuvant Treatment for Colon Cancer
 
Thierry André, M.D., Corrado Boni, M.D., Lamia Mounedji-Boudiaf, M.D., 
Matilde Navarro, M.D., Josep Tabernero, M.D., Tamas Hickish, M.D., 
Clare Topham, M.D., Marta Zaninelli, M.D., Philip Clingan, M.D., 
John Bridgewater, M.D., Isabelle Tabah-Fisch, M.D., 
and Aimery de Gramont, M.D., for the Multicenter International Study 
of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment 
of Colon Cancer (MOSAIC) Investigators
 
From Hôpital Tenon, Paris (T.A.);
GERCOR Oncology Multidisciplinary
Group, Paris (T.A., A.G.); Arcispedale San-
ta Maria Nuova, Reggio Emilia, Italy
(C.B.); Sanofi-Synthelabo, Paris (L.M.-B.,
I.T.-F.); Hospital Duran i Reynals, l’Hospi-
talet de Llobregat, Llobregat, Spain (M.N.);
Vall d’Hebron University Hospital, Barcelo-
na, Spain (J.T.); Dorset Cancer Centre,
Royal Bournemouth and Poole Hospitals,
Bournemouth, United Kingdom (T.H.); Roy-
al Surrey County Hospital, Guildford, Sur-
rey, United Kingdom (C.T.); Ospedale Bor-
gotrento, Verona, Italy (M.Z.); Southern
Medical Day Care Centre, Wollongong, Aus-
tralia (P.C.); North Middlesex Hospital,
London (J.B.); and Hôpital Saint-Antoine,
Paris (A.G.). Address reprint requests to
Dr. de Gramont at Hôpital Saint Antoine,
184 rue du Faubourg Saint Antoine, Paris
75012, France, or at aimery.de-gramont@
sat.ap-hop-paris.fr.
N Engl J Med 2004;350:2343-51.
 




The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL).
Oxaliplatin improves the efficacy of this combination in patients with metastatic colo-





We randomly assigned 2246 patients who had undergone curative resection for stage II
or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary




A total of 1123 patients were randomly assigned to each group. After a median follow-
up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a can-
cer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1
percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at
three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group
given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7)
in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus ox-
aliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastro-
intestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was
12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six




Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant
treatment of colon cancer.
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olorectal cancer is the second
 





; 40 to 50 percent of pa-
tients who undergo potentially curative surgery





 The most important prognostic indicator of
survival in early colon cancer is the stage of the tu-
mor (T, according to the tumor–node–metastasis
[TNM] classification), determined by the depth of
penetration through the bowel wall, and the num-




The demonstration that postoperative adjuvant
treatment with fluorouracil and levamisole reduced
the mortality rate by 33 percent among patients




 prompted several trials,
which established six months of treatment with
fluorouracil plus leucovorin (FL) as the standard ad-




Oxaliplatin is a third-generation platinum deriva-
tive, which, when combined with fluorouracil and
leucovorin, is among the most effective chemo-





determine whether oxaliplatin can also benefit pa-
tients with disease in an earlier stage, we conduct-
ed an international phase 3 clinical trial in patients
with stage II or III colon cancer — the Multicenter
International Study of Oxaliplatin/5-Fluorouracil/





Patients were eligible if they had undergone com-
plete resection of histologically proven stage II (T3
or T4,N0,M0) or stage III (any T,N1 or N2,M0) co-
lon cancer, as defined by the presence of the inferi-
or pole of the tumor above the peritoneal reflection
— that is, at least 15 cm from the anal margin.
Treatment had to be started within seven weeks af-
ter surgery. Other eligibility criteria included an age
of 18 to 75 years; a Karnofsky performance-status
score of at least 60; a carcinoembryonic antigen
level of less than 10 ng per milliliter; the absence of
prior chemotherapy, immunotherapy, or radio-
therapy; and adequate blood counts and liver and
kidney function. Written informed consent was re-
quired from all patients, and the study was ap-





Eligible patients were randomly assigned to receive
FL alone or with oxaliplatin. In the FL group, each
cycle comprised a 2-hour infusion of 200 mg of leu-
covorin per square meter of body-surface area fol-
lowed by a bolus of 400 mg of fluorouracil per
square meter and then a 22-hour infusion of 600
mg of fluorouracil per square meter given on 2 con-
secutive days every 14 days, for 12 cycles. In the
group given FL plus oxaliplatin, the same FL regi-
men was used, plus a two-hour infusion of 85 mg
of oxaliplatin (Eloxatin, Sanofi-Synthelabo) per
square meter on day 1, given simultaneously with





use of disposable pumps (LV5 infusors, Baxter
Healthcare) allowed outpatients to receive a contin-
uous infusion of fluorouracil.
Adverse effects were graded according to the
Common Toxicity Criteria of the National Cancer
Institute, version 1. According to these criteria, a
score of 1 indicates mild adverse effects, a score of
2 moderate adverse effects, a score of 3 severe ad-
verse effects, and a score of 4 life-threatening ad-
verse effects. Dose reductions were based on the
worst adverse effects observed during the previous
cycle. The dose of oxaliplatin was to be reduced to
75 mg per square meter in the event of persistent
(at least 14 days) paresthesias, temporary painful
paresthesias, or functional impairment. Oxalipla-
tin was discontinued in cases of persistent painful
paresthesias or functional impairment. Together
with reductions in the dose of oxaliplatin, the bolus
dose of fluorouracil was reduced to 300 mg per
square meter and the infusion to 500 mg per
square meter in the event of grade 3 or 4 neutrope-
nia or thrombocytopenia (or both), diarrhea, sto-
matitis, or other drug-related adverse effects of
grade 3. Only the dose of fluorouracil was sched-
uled to be reduced in the event of skin-related ad-
verse effects of grade 3 or 4. Treatment was delayed
by up to three weeks until the patient recovered
from various adverse effects, the neutrophil count
exceeded 1500 per cubic millimeter, and the plate-
let count exceeded 100,000 per cubic millimeter.
Chemotherapy was stopped in the event of cardiac





Patients were assessed before randomization, ev-
ery two weeks during treatment, and then every six
c
methods
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months for five years. The baseline assessment
involved a medical history taking, physical exami-
nation, biologic tests, measurement of the carcino-
embryonic antigen level, chest radiography, and
abdominal ultrasonography or computed tomog-
raphy. Patients were monitored for adverse effects
throughout the treatment period and until 28 days
after the last cycle of chemotherapy, unless treat-
ment-related adverse effects required additional
follow-up.
The diagnosis of recurrence was made on the
basis of imaging and, if necessary, cytologic analysis
or biopsy. An elevated carcinoembryonic antigen
level as a solitary finding was not accepted as evi-
dence of relapse. Neurologic adverse effects were to
be reported at each visit during follow-up and were
assessed with the use of the neurosensory section
of the Common Toxicity Criteria of the National




Randomization was performed centrally, and the
minimization method was used to balance treat-
ment allocation according to the TNM stage (T2 or
T3 vs. T4 and N0, N1, or N2), the presence or ab-
sence of bowel obstruction or tumor perforation,
and the medical center. The sample size of 2200
patients was calculated under the assumptions of a
three-year disease-free survival rate of 73 percent in
the control group and 79 percent in the group giv-
en FL plus oxaliplatin, with a ratio of stage II dis-
ease to stage III disease of 0.4:0.6, an enrollment
period and a follow-up period of three years, a de-
crease in the risk of relapse after three years, a sta-
tistical power of 90 percent, and an alpha value of
0.05 and two-sided P values derived with the use of
the log-rank test. The primary efficacy variable was
disease-free survival, defined as the time from ran-
domization to relapse or death, whichever occurred
first. Second colorectal cancers were considered
relapses, whereas noncolorectal tumors were dis-
regarded in the analyses.
The primary statistical analysis of efficacy was
the comparison, after three years of follow-up, of
disease-free survival between groups according to
the intention-to-treat principle, with the use of a
two-sided log-rank test stratified according to base-
line disease stage. Hazard ratios and 95 percent con-
fidence intervals were calculated with the use of the
Cox proportional-hazards model. Survival curves
were drawn according to Kaplan–Meier methods.
To assess the consistency of the effect of treat-
ment on disease-free survival across prognostic
subgroups, we calculated hazard ratios and 95 per-
cent confidence limits for subgroups defined ac-
cording to the following variables: sex, age, disease
stage (II vs. III), baseline serum carcinoembryon-
ic antigen level, number of involved lymph nodes
(≤4 vs. >4), T classification (T4 vs. T1, T2, or T3),
degree of cellular differentiation (well vs. poorly
differentiated), and the presence or absence of per-
foration, obstruction, and venous invasion.
The cutoff date of the analysis was April 22,
2003. The duration of follow-up was defined as the
number of months from randomization to the cut-
off date.
Secondary end points were safety, including
long-term adverse effects, and overall survival, mea-
sured from the time of randomization to death from
any cause. With a median follow-up of three years,
it is too early to compare the two treatment groups
statistically in terms of survival, and only descrip-
tive analyses of overall survival are presented. Safe-
ty analyses included patients who had received at
least one cycle of treatment.
 
organization of the trial
 
The concept underlying this study was developed
by Dr. de Gramont, and the investigation was de-
signed by the investigators and Sanofi-Synthelabo.
Data were collected, managed, and analyzed by the
sponsor. The article was written by the investiga-
tors, on the basis of data and statistical analyses
provided by Sanofi-Synthelabo.
A data and safety monitoring board of indepen-
dent experts reviewed safety data every six months
during the treatment period to provide the sponsor
with independent advice on the progress of the





Between October 1998 and January 2001, 2246 pa-
tients were enrolled at 146 centers in 20 countries:
1123 patients were randomly assigned to receive
FL plus oxaliplatin and 1123 to receive FL without
oxaliplatin. Of these patients, 1108 received at least
one cycle of FL plus oxaliplatin and 1111 received
at least one cycle of FL. The patients’ characteristics
were well matched in the two groups (Table 1). In
both groups, 60 percent of the patients had stage
III disease and 40 percent had stage II disease. The
results
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overall median time between surgery and the start
of chemotherapy was 5.7 weeks (range, 1.1 to 17.0).
 A total of 41 patients (1.8 percent) did not
strictly meet eligibility criteria related to baseline
disease. In one patient in each group, the resection
of primary tumor was incomplete. Four patients in
the group given FL plus oxaliplatin and six in the FL
group had a history of cancer, including colorectal
cancer. Thirteen patients (four in the group given
FL plus oxaliplatin and nine in the FL group) had
stage IV cancer, and three patients (two in the group
given FL plus oxaliplatin and one in the FL group)
had cancer of the middle or lower rectum. Four pa-
tients in the group given FL plus oxaliplatin and





The median number of cycles of chemotherapy re-
ceived was 12 in both groups; 74.7 percent of pa-
tients in the group given FL plus oxaliplatin and
86.5 percent in the FL group received the planned
12 cycles. In the group that received FL plus oxali-
platin, the median dosage of oxaliplatin was 34.2
mg per square meter per week across all cycles re-
ceived and 36.5 mg per square meter per week
across cycles including oxaliplatin. In both cases,
more than 80 percent of the planned dose was ac-
tually given (80.5 percent and 85.9 percent, respec-
tively). The dose of fluorouracil received was 84.4
percent of the planned dose in the group given FL
plus oxaliplatin and 97.7 percent of the planned




Neutropenia, diarrhea, and vomiting were the most
frequent grade 3 or 4 adverse effects in the group
given FL plus oxaliplatin (Table 2). Grade 3 or 4
neutropenia was much commoner with FL plus ox-
aliplatin than with FL (41.1 percent vs. 4.7 percent,
P<0.001) but was complicated by fever or infection
in only 1.8 percent of cases (20 patients) in the
group given FL plus oxaliplatin and in 0.2 percent of
cases (2 patients) in the FL group (P<0.001). The
incidence of thromboembolic events among pa-
tients who received at least one cycle of the as-
signed regimen was similar in the two groups (63
of 1108 patients [5.7 percent] and 72 of 1111 pa-
tients [6.5 percent], respectively). 
Although 92.1 percent of patients treated with FL
plus oxaliplatin had peripheral neuropathy during
treatment, half of these episodes were of grade 1
 
Table 1. Baseline Characteristics of the Patients in the Group Given











Age <65 yr — no. (%) 723 (64.4) 743 (66.2)
Sex — no. (%)
Male 630 (56.1) 588 (52.4)
Female 493 (43.9) 535 (47.6)
Karnofsky performance-status score — no. (%)
 <60 5 (0.4) 5 (0.4) 
 60–70 150 (13.4) 134 (11.9)
 80–100 968 (86.2) 984 (87.6) 
Disease stage — no. (%) 
 II 451 (40.2) 448 (39.9)
 III 672 (59.8) 675 (60.1)
Depth of invasion — no. (%)
 T2 51 (4.5) 54 (4.8)
 T3 853 (76.0) 852 (75.9)
 T4 213 (19.0) 208 (18.5)
Unknown 6 (0.5) 9 (0.8)
Bowel obstruction — no. (%) 201 (17.9) 217 (19.3)
Perforation — no. (%) 78 (6.9) 78 (6.9)
Histologic appearance — no. (%)
 Well differentiated 934 (83.2) 914 (81.4)
 Poorly differentiated 142 (12.6) 148 (13.2)
 Unknown 47 (4.2) 61 (5.4)
 
Patients with stage III disease — no. (%)
 
No. of nodes involved
 1–4 499 (44.4) 513 (45.7)
 >4 170 (15.1) 160 (14.2)
Unknown 2 (0.2) 2 (0.2)
 
Patients with stage II disease — no. (%)
 
T4 84 (18.6) 87 (19.4)
No. of lymph nodes examined
 <10 152 (33.7) 149 (33.3)
 ≥10 295 (65.4) 294 (65.6)
Bowel obstruction 71 (15.7) 87 (19.4)
Perforation 38 (8.4) 43 (9.6)
Histologic appearance
Well differentiated 385 (85.4) 378 (84.4)
Poorly differentiated 47 (10.4) 42 (9.4)
Unknown 19 (4.2) 28 (6.3)
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(Table 3). Of the 137 patients (12.4 percent) who
had grade 3 peripheral neuropathy during treat-
ment, grade 3 symptoms were still present in 8 pa-
tients at the six-month follow-up visit and in 5 pa-
tients at the one-year visit. In 12 patients, grade 3
peripheral neurosensory symptoms appeared after
the end of treatment, and 6 of these patients had
persistent grade 3 symptoms after one year. In total,
11 of 1018 patients (1.1 percent) who were assessed
one year after the end of treatment continued to
have grade 3 peripheral neurosensory symptoms.
This number dropped to five (0.5 percent) after 18
months (Table 3).
Twelve patients — six in each group (0.5 per-
cent) — died within 1 month after the end of treat-
ment; these included three deaths in each group
during the first 60 days of treatment. In the group
given FL plus oxaliplatin, four patients died of in-
fection or sepsis (two with neutropenia) and two of
intracranial hemorrhage. In the FL group, one pa-
tient each died of sepsis, Stevens–Johnson syn-
drome in the context of severe diarrhea and flucon-
azole treatment, and anoxic cerebral infarction;
one patient committed suicide; and two died sud-




There was good compliance with follow-up visits.
The mean time between visits was 5.97 months in
the group given FL plus oxaliplatin and 5.98 months
in the FL group. The median interval was 6.01




* Fisher’s exact test was used to calculate P values. NA denotes not applicable.
† There are only three grades of paresthesia in version 1 of the Common Toxicity Criteria of the National Cancer Institute.
‡ This category included the hand–foot syndrome.
§ There are only two grades of alopecia in version 1 of the Common Toxicity Criteria of the National Cancer Institute. The 
 
incidence of grade 2 alopecia was 5.0 percent in each group.
 
Table 2. Adverse Events in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin and the FL Group.*
Adverse Event FL plus Oxaliplatin (N=1108) FL (N=1111) P Value
 




Paresthesia† 92.0 12.4 NA 15.6 0.2 NA <0.001 0.001
Neutropenia 78.9 28.8 12.3 39.9 3.7 1.0 <0.001 <0.001
Thrombocytopenia 77.4 1.5 0.2 19.0 0.2 0.2 <0.001 0.001
Anemia 75.6 0.7 0.1 66.9 0.3 0.0 <0.001 0.09
Nausea 73.7 4.8 0.3 61.1 1.5 0.3 <0.001 <0.001
Diarrhea 56.3 8.3 2.5 48.4 5.1 1.5 <0.001 <0.001
Vomiting 47.2 5.3 0.5 24.0 0.9 0.5 <0.001 <0.001
Stomatitis 41.6 2.7 0.0 39.6 2.0 0.2 0.34 0.41
Skin‡  31.5 1.4 0.6 35.5 1.7 0.7 0.05 0.67
Alopecia§ 30.2 NA NA 28.1 NA NA 0.28 NA
Allergic reaction 10.3 2.3 0.6 1.9 0.1 0.1 <0.001 <0.001
Thrombosis 
or phlebitis
5.7 1.0 0.2 6.5 1.7 0.1 0.48 0.29
Neutropenia with 
fever or infection 
1.8 1.4 0.4 0.2 0.1 0.1 <0.001 <0.001
 
* Only patients who actually received treatment were included in the analysis. 
A grade of 0 indicates no change or no symptoms, a grade of 1 mild paresthe-
sia and loss of deep tendon reflexes, a grade of 2 mild or moderate objective 
sensory loss and moderate paresthesia, and a grade of 3 severe objective sen-
 
sory loss or paresthesias that interfere with function.
 
Table 3. Incidence of Neurosensory Symptoms during Treatment 




















0 87 (7.9) 424 (38.8) 624 (59.0) 718 (70.5) 738 (76.3)
1 533 (48.2) 439 (40.2) 338 (31.9) 240 (23.6) 191 (19.8)
2 349 (31.6) 174 (15.9) 82 (7.8) 49 (4.8) 33 (3.4)
3 137 (12.4) 55 (5.0) 14 (1.3) 11 (1.1) 5 (0.5)
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At the time of analysis (median follow-up, 37.9
months), 237 patients in the group given FL plus
oxaliplatin (21.1 percent) had relapsed or died, as
compared with 293 (26.1 percent) in the FL group.
The hazard ratio for recurrence in the group given
FL plus oxaliplatin, as compared with the FL group,
was 0.77 (P=0.002), corresponding to a 23 percent
reduction in the risk of relapse. The probability of
disease-free survival at three years was 78.2 percent
(95 percent confidence interval, 75.6 to 80.7 per-
cent) in the group given FL plus oxaliplatin and
72.9 percent (95 percent confidence interval, 70.2
to 75.7 percent) in the FL group (P=0.002 by the
stratified log-rank test) (Table 4 and Fig. 1).
Among patients with stage III disease, the haz-
ard ratio for relapse was 0.76 (95 percent confi-
dence interval, 0.62 to 0.92) in the group given FL
plus oxaliplatin, as compared with the FL group,
and the three-year disease-free survival rate was
72.2 percent and 65.3 percent, respectively (Fig. 2).
Among patients with stage II disease, the hazard
ratio for relapse was 0.80 (95 percent confidence
interval, 0.56 to 1.15) in the group given FL plus
oxaliplatin, as compared with the FL group, and
the three-year disease-free survival rates were 87.0
percent and 84.3 percent, respectively (Fig. 2).
A Cox-model analysis showed that the reduced
risk of recurrence with FL plus oxaliplatin was sim-
ilar in patients with stage II and those with stage III
disease (P=0.77). Calculation of hazard ratios and
95 percent confidence intervals (Fig. 3) showed
that the reduced risk of relapse was consistent in all





At the time of the cutoff date of the primary analy-
sis, 133 patients had died in the group given FL
plus oxaliplatin, as compared with 146 patients in
the FL group (hazard ratio for death, 0.90; 95 per-
cent confidence interval, 0.71 to 1.13), and the prob-
ability of survival at three years was 87.7 percent
and 86.6 percent, respectively. Most of the patients
who died had stage III disease (104 in the group
given FL plus oxaliplatin and 119 in the FL group);
the hazard ratio for death in this subgroup was
0.86 (95 percent confidence interval, 0.66 to 1.11).
In previous trials, the addition of oxaliplatin to
fluorouracil and leucovorin doubled the response
rate and prolonged progression-free survival among





efficacy and safety of this regimen were recently
confirmed in a large, randomized, phase 3 trial,
discussion
 
* FL denotes fluorouracil and leucovorin, and CI confidence interval.
† P=0.002 by the stratified log-rank test for the comparison between groups.
‡ The same patient could have been counted in more than one relapse category 
 
if several types of relapses were reported at the same follow-up visit.
 















Probability of disease-free survival 
at 3 yr — % (95% CI)†
78.2 (75.6–80.7) 72.9 (70.2–75.7)
Event — no. (%)
Relapse‡
Metastasis












Death without relapse 29 (2.6) 14 (1.2)
 
Figure 1. Kaplan–Meier Estimates of Disease-free Survival  in the Group Giv-
en Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin, 
According to the Intention to Treat.
 
The hazard ratio for recurrence in the group given FL plus oxaliplatin, as com-
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which found that this approach was superior (with
respect to all efficacy variables, including overall
survival) to the combination of irinotecan, fluoro-





was designed to test the efficacy of adjuvant treat-
ment with the regimen of FL plus oxaliplatin. We
chose disease-free survival as the primary end





that the absence of relapse is the best indicator of
efficacy, since it relates directly to the effect of the
treatment under investigation. By allowing early
appraisal of the results, the use of three-year dis-
ease-free survival as the primary end point for adju-
vant trials of patients with colon cancer should per-
mit rapid evaluation of new treatments. Whether
disease-free survival should be a primary end point
is still under discussion, but a recent analysis of
several studies supports the appropriateness of the
use of three-year disease-free survival as a good
predictor of five-year overall survival in trials of ad-




Disease-free survival in the FL group in our
study falls within the highest range reported in





 The improvement in disease-free
survival among patients who were treated with FL
plus oxaliplatin corresponds to a relative reduction
in the risk of recurrence of 23 percent. Since most
relapses after curative surgery occur within the first
three years, we consider our results in this respect
to be complete.
Although it is agreed that patients with stage III
disease benefit from adjuvant treatment, whether
all patients with stage II disease should receive
such treatment remains debatable. This controver-
sy was sustained for years by the contradictory con-
clusions of two large groups of investigators. The
National Surgical Adjuvant Breast and Bowel
Project concluded that the relative benefits of treat-





 whereas the International Multicen-
tre Pooled Analysis of B2 Colon Cancer Trials
(IMPACT B2) failed to demonstrate a statistically









which evaluated individual data on 3300 patients
who were enrolled in five randomized trials, in-
cluding those analyzed in IMPACT B2, concluded
that patients with stage II disease could benefit
from adjuvant chemotherapy, but to a lesser extent
than patients with stage III tumors. Indeed, the ab-
solute benefit among patients with stage II disease
is only half as great as that among patients with
stage III disease, and twice as many patients with
stage II tumors are required in such studies in or-
der to detect a difference. 
 
Figure 2. Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) 
and the Group Given FL plus Oxaliplatin, According to the Stage of Disease and the Intention to Treat.
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A test for interaction is an appropriate statistical
approach to the question of whether the benefit of
adjuvant treatment differs between stage II and




 In our study, this test
showed no significant interaction between the stage
of disease and the treatment, indicating that FL
plus oxaliplatin benefited both stage II and stage
III colorectal cancer. From a clinical standpoint,
stage II colon cancer occurs in a heterogeneous,
node-negative population in which clinical and bi-
ologic prognostic factors other than the status of
lymph-node involvement need to be taken into ac-
count. Tools are being developed to help physi-
cians assess the risk–benefit ratio of adjuvant che-




With no clear consensus on the most effective
FL regimen to be used for adjuvant treatment, we
chose a twice-monthly regimen because of its effi-
cacy and low rates of adverse effects in patients






decision are recent results demonstrating that this
approach to adjuvant therapy is less toxic than





 This approach led to a straightforward study
design, since the treatment in both groups was
similar except for the addition of oxaliplatin in the
group given FL plus oxaliplatin. The improved dis-
ease-free survival in the FL-plus-oxaliplatin group
is thus directly linked to oxaliplatin.
The main safety concern regarding the use of
oxaliplatin is peripheral neuropathy. Oxaliplatin in-
duces frequent, transient, distal paresthesias dur-
ing or shortly after the first minutes of infusion. In
some cases these neurosensory symptoms increase
in intensity with cumulative doses, persist between





 We observed grade 3 periph-
eral neuropathy in 12.4 percent of patients who
were receiving oxaliplatin. At one year, 11 patients
(1.1 percent) had grade 3 neuropathy. Among them,
two were found to have underlying disease that
could have caused these symptoms (diabetes and
hemiplegia, respectively). Although more frequent
among patients receiving FL plus oxaliplatin than
among those treated with FL alone, grade 3 or 4 neu-
tropenia led to fever or infection in only 1.8 percent
of patients in the former group. Similar findings





 From a safety standpoint,
the rate of death from any cause was similarly low
during treatment in both groups and, at 0.5 per-





Figures for overall survival at this stage of the
study are preliminary, and no conclusion can be
drawn about differences in survival between the
treatment groups. Since the median overall surviv-
al from the time of diagnosis of metastatic colorec-
 
Figure 3. Hazard Ratios and 95 Percent Confidence Intervals for Recurrence 
in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin, 
as Compared with the FL Group, According to Baseline Prognostic Factors 
and the Intention to Treat.
 
CEA denotes carcinoembryonic antigen.
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expect that the effect of oxaliplatin on survival will
become apparent within the next 2 years.
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